SpaceX's Gwynne Shotwell Sees Starlink Becoming Profitable In 2024, Bets On Starship Making It One Of The Most Valuable Companies Amid Reports Of Tender Offer Valuing It Over $250B
Celltrion presents additional data from phase III randomized controlled trials to further support biosimilarity for CT-41 (biosimilar candidate of denosumab) and CT-P47 (biosimilar candidate of tocili